EUVIMEDEUVIMED entdecken
Crossref

Predictive Value of Pretransplant Cytomegalovirus-Specific Cellular Immunity for Posttransplant CMV Infection in Liver Transplant Recipients Under Antiviral Prophylaxis

Elif Seren Tanriverdi, Yusuf Yakupogullari, Yasar Bayindir, Sami Akbulut, Sibel Altunisik Toplu, Harika Gozde Gozukara Bag, Burak Isik, Baris Otlu, Sezai Yilmaz

Transplantation Proceedings · 2025

DOI: 10.1016/j.transproceed.2025.07.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Elif Seren Tanriverdi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Inonu University Faculty of Medicine, Malatya, Türkiye. Electronic address: seren.tanriverdi@inonu.edu.tr. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Liver Transplantation, Antiviral Agents, Cytomegalovirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Inonu University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Existing data suggest that cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) in solid organ recipients may predict post-transplant CMV infection, but the available information is still limited, and needs to be validated for larger patient populations under certain circumstances. This study aimed to determine whether CMV-CMI could predict post-transplant CMV infection in liver transplant recipients (LTRs) receiving antiviral prophylaxis (AVP). METHODS: A total of 1769 LTRs at the Inonu University Liver Transplantation Institute were retrospectively analyzed. CMV-CMI in a total of 334 patients (> 91% were CMV donor [D] positive/recipient [R] positive) who received AVP were analyzed using the CMV-Interferon (CMV-QF; QuantiFERON-CMV, Qiagen, Germany) assay within the week before transplantation. Patients were divided into two groups: group 1 (positive; n = 171, 51.2%) and group 2 (negative; n = 163, 48.8%). Patient variables were analyzed statistically. RESULTS: A total of 124 LTRs developed CMV infection. Patients' pre-transplant characteristics did not differ significantly by their CMV-CMI result. A significantly lower percentage of LTRs with CMV-CMI positive developed infection than those with negatives (7.6% vs 68.1%, P < .001). All CMV-CMI positive patients fully recovered with antiviral treatment but only 76.6% of LTRs with negative CMV-CMI (P = .032). Logistic regression analysis showed that a negative CMV-CMI was associated with a 26 times increased risk of CMV infection compared to those with positive CMV-CMI (odds ratio [OR] = 25.9, P < .001). Female recipients developed CMV infection earlier after cessation of AVP than male recipients (median = 128 vs 144 days, P = .038). CONCLUSIONS: The pre-transplant status of CMV-CMI may be a strong indicator of post-transplant CMV infection for LTRs receiving AVP. Therefore, further consideration should be made for the LTRs with negative CMV-CMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsLiver TransplantationAntiviral AgentsCytomegalovirusImmunity, CellularHumansMaleFemaleMiddle AgedRetrospective StudiesAdultPredictive Value of TestsRisk Factors

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medical Microbiology, Inonu University Faculty of Medicine, Malatya, Türkiye. Electronic address: seren.tanriverdi@inonu.edu.tr.
  • Department of Medical Microbiology, Inonu University Faculty of Medicine, Malatya, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Guven Health Group Guven Private Hospital Ayrancı, Ankara, Türkiye.
  • Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Inonu University Faculty of Medicine, Malatya, Türkiye.
  • Department of Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya, Türkiye.

Förderung

  • Inonu University

Zitieren

APA

Tanriverdi, E. S., Yakupogullari, Y., Bayindir, Y., Akbulut, S., Toplu, S. A., Bag, H. G. G., Isik, B., Otlu, B., & Yilmaz, S. (2025). Predictive Value of Pretransplant Cytomegalovirus-Specific Cellular Immunity for Posttransplant CMV Infection in Liver Transplant Recipients Under Antiviral Prophylaxis. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.07.006

Vancouver

Tanriverdi ES, Yakupogullari Y, Bayindir Y, Akbulut S, Toplu SA, Bag HGG, et al. Predictive Value of Pretransplant Cytomegalovirus-Specific Cellular Immunity for Posttransplant CMV Infection in Liver Transplant Recipients Under Antiviral Prophylaxis. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.07.006

BibTeX
@article{Tanriverdi2025,
  author = {Tanriverdi, Elif Seren and Yakupogullari, Yusuf and Bayindir, Yasar and Akbulut, Sami and Toplu, Sibel Altunisik and Bag, Harika Gozde Gozukara and Isik, Burak and Otlu, Baris and Yilmaz, Sezai},
  title = {Predictive Value of Pretransplant Cytomegalovirus-Specific Cellular Immunity for Posttransplant CMV Infection in Liver Transplant Recipients Under Antiviral Prophylaxis},
  journal = {Transplantation Proceedings},
  year = {2025},
  doi = {10.1016/j.transproceed.2025.07.006}
}
Kostenlos starten →